Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054912 · ClinicalTrials.gov registry record · Phase 1
An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer
A Phase 1 study of Colorectal Neoplasms and Colonic Neoplasms, sponsored by Epimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 9
- Study locations
NCT00054912 is a Phase 1 study of Colorectal Neoplasms and Colonic Neoplasms that has completed, run by Epimmune. The registered enrollment target is 18 participants, below the 576-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT00054912, a Phase 1 study of Colorectal Neoplasms and Colonic Neoplasms, has completed, sponsored by Epimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 9
- Study locations
Study Summary
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Colon Cancer.
Conditions Studied
Interventions
- BIOLOGICAL EP2101
Study Locations (9)
California
- University of Southern California School of Medicine - Los Angeles
- University of California, San Diego - San Diego
Texas
- Mary Crowley Medical Research Center - Dallas
- Tyler Cancer Center - Tyler
Washington
- University of Washington - Seattle
- Cancer Care Northwest - Spokane
Florida
- Cancer Centers of Florida - Orlando
New York
- New York Oncology Hematology - Albany
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2003-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054912
The ClinicalTrials.gov registry entry for NCT00054912 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 576-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Epimmune, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which EP2101 is the first listed.
NCT00054912 reports 9 study locations spanning 6 distinct geographic areas - top geographies include California, Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT00054912 about?
NCT00054912 is a clinical study titled "An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer". EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating ...
What is the current status of trial NCT00054912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2003-02.
What conditions does trial NCT00054912 study?
This clinical trial studies the following conditions: Colorectal Neoplasms, Colonic Neoplasms.
What interventions are being tested in trial NCT00054912?
The interventions under investigation include: EP2101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00054912?
This trial is sponsored by Epimmune, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00054912 being conducted?
This trial has 9 study locations across California, Florida, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.